✦ LIBER ✦

Adjuvant 5-FU based therapy for colorectal cancer

✍ Scribed by A. Muñoz; I. Rubio; J.M. Mañé; J.R. Barceló; R. Fernández; G. Abón; N. Fuente; G. López-Vivanco

Book ID: 117667232
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 114 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(99)80682-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant therapy for colorectal cancer

✍ M. Lise; A. Gerard; D. Nitti; D. Zane; M. Buyse; N. Duez; J. P. Arnaud; U. Metzg 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 721 KB

Adjuvant therapy for colorectal cancer

✍ Kirby I Bland 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Adjuvant therapy of colorectal cancer

✍ Massimo Lopez 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 513 KB

Adjuvant therapy for patients with color

Adjuvant therapy for patients with colorectal cancer

✍ Glenn Steele 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 502 KB

Adjuvant and palliative therapy for colo

Adjuvant and palliative therapy for colorectal cancer

✍ B. Glimelius 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Survival after adjuvant 5-FU treatment f

Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer

✍ Wouter H. de Vos tot Nederveen Cappel; Hielke J. Meulenbeld; Jan H. Kleibeuker; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 67 KB 👁 2 views

## Abstract __In vitro__ studies suggest that a deficient mismatch repair (MMR) system reduces 5‐Fluorouracil cytotoxicity. Colon cancer (CC) in hereditary nonpolyposis colorectal cancer (HNPCC) is due to a dysfunctioning MMR gene that leads to microsatellite instability (MSI). Clinical studies on